BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 23524209)

  • 1. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
    J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
    Int J Cardiol; 2013 Sep; 167(6):2682-7. PubMed ID: 22795403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
    Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C
    Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation.
    Nakagawa K; Hirai T; Takashima S; Fukuda N; Ohara K; Sasahara E; Taguchi Y; Dougu N; Nozawa T; Tanaka K; Inoue H
    Am J Cardiol; 2011 Mar; 107(6):912-6. PubMed ID: 21247518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Olesen JB; Fauchier L; Lane DA; Taillandier S; Lip GYH
    Chest; 2012 Jan; 141(1):147-153. PubMed ID: 21680645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).
    Roldán V; Marín F; Fernández H; Manzano-Fernández S; Gallego P; Valdés M; Vicente V; Lip GY
    Am J Cardiol; 2013 Apr; 111(8):1159-64. PubMed ID: 23337836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.
    Lip GY; Frison L; Halperin JL; Lane DA
    Stroke; 2010 Dec; 41(12):2731-8. PubMed ID: 20966417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score.
    Chao TF; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Hsieh MH; Chen SA
    Can J Cardiol; 2014 Apr; 30(4):405-12. PubMed ID: 24582725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population.
    Poli D; Lip GY; Antonucci E; Grifoni E; Lane D
    J Cardiovasc Electrophysiol; 2011 Jan; 22(1):25-30. PubMed ID: 20653814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation.
    Abu-Assi E; Otero-Raviña F; Allut Vidal G; Coutado Méndez A; Vaamonde Mosquera L; Sánchez Loureiro M; Caneda Villar MC; Fernández Villaverde JM; Maestro Saavedra FJ; González-Juanatey JR;
    Int J Cardiol; 2013 Jun; 166(1):205-9. PubMed ID: 22104995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients.
    Naccarelli GV; Panaccio MP; Cummins G; Tu N
    Am J Cardiol; 2012 May; 109(10):1526-33. PubMed ID: 22360819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GYH
    Chest; 2014 Jun; 145(6):1370-1382. PubMed ID: 24356875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.